

5 July 2016

GlucoControl Momentum

Highlights

- A significant second manufacturing order has been received for GlucoControl™, corresponding with commencement of increased consumer marketing
- Marketing programs ramping up with product availability
- 'Diet for Diabetes' educational seminars being held across Australia
- Significant progress on distribution agreements for US, UK and China

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omniblend Innovation, the medical technology company focused on foods for special medical purposes.

Manufacturing and Distribution Momentum

A second large manufacturing order for GlucoControl™ has been received to provide additional volume of stock for distribution into selected pharmacies. This second production will increase the availability of GlucoControl™ in pharmacy outlets across Australia and will coincide with marketing programs designed to build product and brand awareness.

Promotional and Educational 'Diet for Diabetes' Seminars

As part of its marketing program, Omniblend Innovation held a promotional information session at the University of WA on 30 May 2016. The event included a panel discussion and Q&A session and was presented by Professor Peter Clifton, a prominent endocrinologist and Professor of Nutrition at the University of South Australia. The seminar was very well attended with representatives from Diabetes WA, as well as medical practitioners, pharmacists, dieticians and diabetes educators.



Picture 1: Professor Peter Clifton from the University of South Australia, presenting at the 'Diets for Diabetes' evening

Following the success of the event, an additional event is planned in Melbourne on 12 July 2016, with further seminars to be held in the coming months in Sydney, Brisbane, Gold Coast and Adelaide. For further information about upcoming events please contact the Company by emailing info@eveinvestments.com.au

Marketing Programs

Omniblend Innovation in conjunction with Faulding will shortly be commencing an active marketing campaign for GlucoControl™ that will incorporate print, radio and television media. This program will coincide with diabetes week on the 10th July and will run for several weeks. Additionally Omniblend Innovation will be presenting the product at various conferences and industry related seminars. It recently showcased the product at the Australia-China Complementary Health Products Expo 2016, which was held in Melbourne between 27 and 29 June 2016.

Further Validation through Ongoing Clinical Trials

A number of further clinical trials are being conducted in Australia, which involve the GlucoControl™ product, which are being funded under grants won by the respective universities conducting the trials. These include the Centre of Research Excellence in Translating Nutritional Science to Good Health Trial and the Deakin University Trial (details of both trials follow).

Centre of Research Excellence in Translating Nutritional Science to Good Health Trial

The Centre of Research Excellence in Translating Nutritional Science to Good Health, in conjunction with the University of Adelaide and Royal Adelaide Hospital, are currently conducting a trial utilising GlucoControl™. This clinical trial is funded by the university and involves:

- i. people in the early stages of diabetes;
- ii. 50 people taking GlucoControl™ pre-meal drink twice a day (before breakfast and before the evening meal) - these are compared with a separate group of 50 people taking a pre-meal drink with no bioactive ingredients; and
- iii. measurement of many diabetes parameters such as HbA1c, gut hormones, weight, muscle-fat ratio.

Interim results from the trial, which has already reached its halfway point, will be presented publicly for the first time at a forthcoming European Association for the Study of Diabetes (EASD) conference in Munich in September 2016.

Deakin University Trial

A trial is also being conducted by Deakin University's Centre for Physical Activity and Nutrition Research. This trial follows 100 people with Type 2 Diabetes for 6 months. Participants take GlucoControl™ (plus a vitamin D supplement) before breakfast and after a weight-training exercise. It will also compare diabetes outcomes with another 100 people who will just do the weight training exercise. Results for this trial are expected either later this year or early next year.

Encouraging Progress with Distribution Agreements

Omniblend Innovation continues to progress negotiations for its patented pre-meal drink for people living with Type 2 Diabetes with potential distributors in the United States, China and the United Kingdom. The Company anticipates providing a further update later this month.

EVE currently holds a ~25% interest in Omniblend Innovation which is expected to increase to a ~40% holding by 30 September 2016.

Ends

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au